More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

Glucagon-like peptide-1 (GLP-1) agonist are a family of medications that help manage blood sugar in patients with type 2 ...

X Biopharma Ltd. (SG:42C) has released an update. iX Biopharma Ltd. announced that its novel semaglutide sublingual wafer, iXB 401, achieved 20 ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major cardiovascular events in diabetic patients were modest and not as robust as ...

Courts have long deferred to CMS’s decisions on implementation of laws that govern Medicare. The overturning of the Chevron ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

The study showed that Rybelsus, the company's oral form of semaglutide, slashed the risk of major cardiovascular events by 14% in type 2 diabetes patients who also face cardiovascular or kidney ...

Please note that NVO already markets oral semaglutide in the United States under the brand name Rybelsus. It is administered once daily and comes in three approved doses, 3 mg, 7 mg and 14 mg.